These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Therapeutic monitoring of immunosuppressive drugs: interest of calcineurin activity assessment in liver transplantation]. Blanchet B Ann Pharm Fr; 2008 Mar; 66(2):96-101. PubMed ID: 18570908 [TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Sommerer C; Konstandin M; Dengler T; Schmidt J; Meuer S; Zeier M; Giese T Transplantation; 2006 Nov; 82(10):1280-5. PubMed ID: 17130775 [TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Fukudo M; Yano I; Masuda S; Fukatsu S; Katsura T; Ogura Y; Oike F; Takada Y; Tanaka K; Inui K Clin Pharmacol Ther; 2005 Aug; 78(2):168-81. PubMed ID: 16084851 [TBL] [Abstract][Full Text] [Related]
25. Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients. Caruso R; Perico N; Cattaneo D; Piccinini G; Bonazzola S; Remuzzi G; Gaspari F Clin Chem; 2001 Sep; 47(9):1679-87. PubMed ID: 11514403 [TBL] [Abstract][Full Text] [Related]
26. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring. Ventura E; Bonardet A; Pageaux GP; Mourad G; Cristol JP Transplant Proc; 2009 Mar; 41(2):707-9. PubMed ID: 19328963 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic drug monitoring of cyclosporine. Jorga A; Holt DW; Johnston A Transplant Proc; 2004 Mar; 36(2 Suppl):396S-403S. PubMed ID: 15041374 [TBL] [Abstract][Full Text] [Related]
29. Assessment of the in vivo immunosuppressive activity of the major cyclosporine metabolite by leukemia allograft rejection. Freed BM; Bennett JA; Rosano TG; Brooks CA; Cramer SM; Lempert N Transplantation; 1992 Feb; 53(2):456-60. PubMed ID: 1738941 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of interleukin-2 mRNA in whole blood as a parameter for monitoring cyclosporine pharmacodynamics. Kuzuya T; Kobayashi T; Katayama A; Nagasaka T; Miwa Y; Uchida K; Nakao A; Yamada K Biol Pharm Bull; 2009 Apr; 32(4):604-8. PubMed ID: 19336891 [TBL] [Abstract][Full Text] [Related]
31. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients. Koefoed-Nielsen PB; Karamperis N; Jørgensen KA Transplant Proc; 2005 May; 37(4):1736-8. PubMed ID: 15919449 [TBL] [Abstract][Full Text] [Related]
32. Recovery of blood mononuclear cell calcineurin activity segregates two populations of renal transplant patients with different sensitivities to cyclosporine inhibition. Piccinini G; Gaspari F; Signorini O; Remuzzi G; Perico N Transplantation; 1996 May; 61(10):1526-31. PubMed ID: 8633383 [TBL] [Abstract][Full Text] [Related]
33. Comparison of predose vs 2-h postdose blood metabolites/cyclosporine ratios in kidney and liver transplant patients. Fernández-Marmiesse A; Hermida J; Tutor JC Clin Biochem; 2000 Jul; 33(5):383-6. PubMed ID: 11018690 [TBL] [Abstract][Full Text] [Related]
34. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289 [TBL] [Abstract][Full Text] [Related]
35. Variation in leukocyte subset concentrations affects calcineurin activity measurement: implications for pharmacodynamic monitoring strategies. van Rossum HH; Romijn FP; Sellar KJ; Smit NP; van der Boog PJ; de Fijter JW; van Pelt J Clin Chem; 2008 Mar; 54(3):517-24. PubMed ID: 18218723 [TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamic monitoring of the immunosuppressive therapy in patients after heart transplantation: whole blood flow cytometric analysis of lymphocyte function. Barten MJ; Rahmel A; Boldt A; Dhein S; Bittner HB; Tarnok A; Mohr FW; Gummert JF Comput Biol Med; 2007 Oct; 37(10):1367-73. PubMed ID: 17182025 [TBL] [Abstract][Full Text] [Related]
37. Calcineurin activity in children with renal transplants receiving cyclosporine. Quien RM; Kaiser BA; Dunn SP; Kulinsky A; Polinsky M; Baluarte HJ; Batiuk TD; Halloran PF Transplantation; 1997 Nov; 64(10):1486-9. PubMed ID: 9392319 [TBL] [Abstract][Full Text] [Related]
38. New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. Brunet M; Millán O; Jiménez O; Campistol JM; Vidal E; Rojo I; Oppenheimer F; Fortuna V; Martorell J Transplant Proc; 2004 Mar; 36(2 Suppl):437S-441S. PubMed ID: 15041382 [TBL] [Abstract][Full Text] [Related]
39. Therapeutic drug monitoring of cyclosporine Neoral in de novo Chinese cardiac transplant recipients treated with an everolimus-cyclosporine immunosuppressive regimen. Wang CH; Chou NK; Wu FL; Ko WJ; Tsao CI; Chi NH; Hsu RB; Wang SS Transplant Proc; 2006 Sep; 38(7):2132-4. PubMed ID: 16980022 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2). Brunet M; Campistol JM; Millán O; Vidal E; Esforzado N; Rojo I; Jiménez O; Oppenheimer F; Corbella J; Martorell J Int Immunopharmacol; 2003 Jul; 3(7):987-99. PubMed ID: 12810356 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]